^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vinblastine

    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    6d
    Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (clinicaltrials.gov)
    P=N/A, N=118, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2027 --> Jun 2026 | Trial primary completion date: May 2027 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine
    8d
    Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (clinicaltrials.gov)
    P=N/A, N=118, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine
    10d
    EA8192: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (clinicaltrials.gov)
    P2/3, N=131, Recruiting, National Cancer Institute (NCI) | N=249 --> 131
    Enrollment change
    |
    MSI (Microsatellite instability) • CD4 (CD4 Molecule)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • methotrexate IV
    10d
    PLRG-HL05: Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) (2026-525263-41-00)
    P2/3, N=370, Not yet recruiting, Polska Grupa Badawcza Chloniakow
    New P2/3 trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • etoposide IV • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine
    12d
    Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors (clinicaltrials.gov)
    P1/2, N=63, Terminated, Centre Oscar Lambret | Trial completion date: Jan 2027 --> Dec 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> May 2025; Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026).
    Trial completion date • Trial termination • Trial primary completion date • IO biomarker
    |
    Opdivo (nivolumab) • capecitabine • cyclophosphamide • vinblastine
    15d
    Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study. (PubMed, J Clin Oncol)
    Neoadjuvant ddMVAC plus durvalumab demonstrated encouraging pCR rates, favorable early survival outcomes, and manageable safety profile. Adding tremelimumab provides similar pCR but worse toxicity. These results support further study of ddMVAC plus durvalumab as a neoadjuvant chemoimmunotherapy strategy for localized MIBC, to be evaluated in comparative trials within an evolving perioperative treatment landscape.
    P1/2 data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 underexpression • PD-L1 negative
    |
    cisplatin • Imfinzi (durvalumab) • doxorubicin hydrochloride • Imjudo (tremelimumab-actl) • methotrexate • vinblastine • Neulasta (pegfilgrastim)
    19d
    Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=49, Completed, Northwestern University | Unknown status --> Completed
    Trial completion
    |
    Adcetris (brentuximab vedotin) • dacarbazine • vinblastine
    19d
    RETAIN BLADDER: Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) (clinicaltrials.gov)
    P2, N=78, Completed, Fox Chase Cancer Center | Active, not recruiting --> Completed | Trial completion date: Feb 2034 --> Dec 2025 | Trial primary completion date: Feb 2027 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    cisplatin • 5-fluorouracil • doxorubicin hydrochloride • mitomycin • vinblastine
    20d
    Adult-Onset Multisystem Langerhans Cell Histiocytosis: Atypical Skeletal and Endocrine Manifestations. (PubMed, Cureus)
    The patient was treated with vinblastine and prednisolone, along with desmopressin and somatotropin replacement. Zoledronic acid was added for osseous disease...This case highlights an unusual presentation of adult LCH with distal lower-extremity and tarsal bone involvement, as well as hypothalamic-pituitary disease preceding osseous diagnosis by two years. It underscores the importance of considering LCH in adults with unexplained multifocal lytic bone lesions and endocrine dysfunction, and it demonstrates that durable disease control can be achieved with systemic therapy.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E
    |
    zoledronic acid • vinblastine
    21d
    Langerhans Cell Histiocytosis Associated With Chronic Myeloid Leukemia: A Pediatric Case Report. (PubMed, Cancer Rep (Hoboken))
    This rare association of CML with LCH expands the recognized spectrum of LCH-associated malignancies. It underscores the importance of long-term surveillance in LCH patients, with particular vigilance for secondary malignancies. It also highlights the need for further research into possible biological relationships between histiocytic and myeloid neoplasms.
    Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    imatinib • cladribine • vinblastine
    21d
    ACCELERATE: Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL (clinicaltrials.gov)
    P2, N=20, Recruiting, New York Medical College | Active, not recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • vinblastine
    23d
    Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma (clinicaltrials.gov)
    P2, N=293, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Apr 2026 --> Apr 2029
    Trial completion date
    |
    cisplatin • erlotinib • carboplatin • cyclophosphamide • etoposide IV • vincristine • topotecan • vinblastine • methotrexate IV